Pharmacokinetic studies of [14C]-flumecinol in humans

I. Klebovich, J. Csetenyi, S. Kerpel-Fronius, L. Vereczkey

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of 14C-labelled 3-trifluoromethyl-α-ethylbenzhydrol (flumecinol, RGH-3332, Zixoryn®), a hepatic enzyme inducer, has been studied in 6 male healthy volunteers after a single oral dose of 100 mg (11.1 Mbq; 300 μCi). Flumecinol concentration in plasma was determined (0-96 h) by capillary gas-liquid chromatography. Total radioactivity was assayed by liquid scintillation counting. The peak concentration of unchanged flumecinol in the plasma (130.2 ± 37.7 ng/ml S.D.) was detected 2.1 h after dosing. The maximum total radioactivity concentration (1414.4 ± 158.9 ng eq./ml) was found at 2.3 h. The ratio of the plasma radioactivity level to unchanged flumecinol indicated a rapid metabolic transformation and a marked first-pass effect in man. A two-compartment open model was constructed to describe the pharmacokinetics of the drug. The unchanged drug was eliminated from plasma with a biological half-life of 20.7 ± 1.8 h giving a total body clearance value of 100.9 ± 33.8 l/h. The volume of distribution of flumecinol was found to be 41.4 ± 18.4 l/kg. However, the biological half-life of total radioactivity was much longer (35.2 ± 11.9 h) than that of the decrease of unchanged drug. The value of total body clearance (4.1 ± 0.6 l/h) and volume of distribution (3.2 ± 1.6 l/kg) were found to be much lower than that of unchanged flumecinol. Radioactivity excreted with urine was 78.8 ± 5.9% and with faeces 12.0 ± 5.3% during 120 h.

Original languageEnglish
Pages (from-to)368-371
Number of pages4
JournalArzneimittel-Forschung
Volume37
Issue number3
Publication statusPublished - 1987

Fingerprint

Pharmacokinetics
Radioactivity
Plasmas
Half-Life
Pharmaceutical Preparations
Scintillation Counting
flumecinol
Liquid chromatography
Scintillation
Feces
Gas chromatography
Gas Chromatography
Healthy Volunteers
Urine
Liver
Liquids
Enzymes

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Pharmacokinetic studies of [14C]-flumecinol in humans. / Klebovich, I.; Csetenyi, J.; Kerpel-Fronius, S.; Vereczkey, L.

In: Arzneimittel-Forschung, Vol. 37, No. 3, 1987, p. 368-371.

Research output: Contribution to journalArticle

Klebovich, I, Csetenyi, J, Kerpel-Fronius, S & Vereczkey, L 1987, 'Pharmacokinetic studies of [14C]-flumecinol in humans', Arzneimittel-Forschung, vol. 37, no. 3, pp. 368-371.
Klebovich, I. ; Csetenyi, J. ; Kerpel-Fronius, S. ; Vereczkey, L. / Pharmacokinetic studies of [14C]-flumecinol in humans. In: Arzneimittel-Forschung. 1987 ; Vol. 37, No. 3. pp. 368-371.
@article{9d2376b9f637439ea0e01fd5f2fc7970,
title = "Pharmacokinetic studies of [14C]-flumecinol in humans",
abstract = "The pharmacokinetics of 14C-labelled 3-trifluoromethyl-α-ethylbenzhydrol (flumecinol, RGH-3332, Zixoryn{\circledR}), a hepatic enzyme inducer, has been studied in 6 male healthy volunteers after a single oral dose of 100 mg (11.1 Mbq; 300 μCi). Flumecinol concentration in plasma was determined (0-96 h) by capillary gas-liquid chromatography. Total radioactivity was assayed by liquid scintillation counting. The peak concentration of unchanged flumecinol in the plasma (130.2 ± 37.7 ng/ml S.D.) was detected 2.1 h after dosing. The maximum total radioactivity concentration (1414.4 ± 158.9 ng eq./ml) was found at 2.3 h. The ratio of the plasma radioactivity level to unchanged flumecinol indicated a rapid metabolic transformation and a marked first-pass effect in man. A two-compartment open model was constructed to describe the pharmacokinetics of the drug. The unchanged drug was eliminated from plasma with a biological half-life of 20.7 ± 1.8 h giving a total body clearance value of 100.9 ± 33.8 l/h. The volume of distribution of flumecinol was found to be 41.4 ± 18.4 l/kg. However, the biological half-life of total radioactivity was much longer (35.2 ± 11.9 h) than that of the decrease of unchanged drug. The value of total body clearance (4.1 ± 0.6 l/h) and volume of distribution (3.2 ± 1.6 l/kg) were found to be much lower than that of unchanged flumecinol. Radioactivity excreted with urine was 78.8 ± 5.9{\%} and with faeces 12.0 ± 5.3{\%} during 120 h.",
author = "I. Klebovich and J. Csetenyi and S. Kerpel-Fronius and L. Vereczkey",
year = "1987",
language = "English",
volume = "37",
pages = "368--371",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic studies of [14C]-flumecinol in humans

AU - Klebovich, I.

AU - Csetenyi, J.

AU - Kerpel-Fronius, S.

AU - Vereczkey, L.

PY - 1987

Y1 - 1987

N2 - The pharmacokinetics of 14C-labelled 3-trifluoromethyl-α-ethylbenzhydrol (flumecinol, RGH-3332, Zixoryn®), a hepatic enzyme inducer, has been studied in 6 male healthy volunteers after a single oral dose of 100 mg (11.1 Mbq; 300 μCi). Flumecinol concentration in plasma was determined (0-96 h) by capillary gas-liquid chromatography. Total radioactivity was assayed by liquid scintillation counting. The peak concentration of unchanged flumecinol in the plasma (130.2 ± 37.7 ng/ml S.D.) was detected 2.1 h after dosing. The maximum total radioactivity concentration (1414.4 ± 158.9 ng eq./ml) was found at 2.3 h. The ratio of the plasma radioactivity level to unchanged flumecinol indicated a rapid metabolic transformation and a marked first-pass effect in man. A two-compartment open model was constructed to describe the pharmacokinetics of the drug. The unchanged drug was eliminated from plasma with a biological half-life of 20.7 ± 1.8 h giving a total body clearance value of 100.9 ± 33.8 l/h. The volume of distribution of flumecinol was found to be 41.4 ± 18.4 l/kg. However, the biological half-life of total radioactivity was much longer (35.2 ± 11.9 h) than that of the decrease of unchanged drug. The value of total body clearance (4.1 ± 0.6 l/h) and volume of distribution (3.2 ± 1.6 l/kg) were found to be much lower than that of unchanged flumecinol. Radioactivity excreted with urine was 78.8 ± 5.9% and with faeces 12.0 ± 5.3% during 120 h.

AB - The pharmacokinetics of 14C-labelled 3-trifluoromethyl-α-ethylbenzhydrol (flumecinol, RGH-3332, Zixoryn®), a hepatic enzyme inducer, has been studied in 6 male healthy volunteers after a single oral dose of 100 mg (11.1 Mbq; 300 μCi). Flumecinol concentration in plasma was determined (0-96 h) by capillary gas-liquid chromatography. Total radioactivity was assayed by liquid scintillation counting. The peak concentration of unchanged flumecinol in the plasma (130.2 ± 37.7 ng/ml S.D.) was detected 2.1 h after dosing. The maximum total radioactivity concentration (1414.4 ± 158.9 ng eq./ml) was found at 2.3 h. The ratio of the plasma radioactivity level to unchanged flumecinol indicated a rapid metabolic transformation and a marked first-pass effect in man. A two-compartment open model was constructed to describe the pharmacokinetics of the drug. The unchanged drug was eliminated from plasma with a biological half-life of 20.7 ± 1.8 h giving a total body clearance value of 100.9 ± 33.8 l/h. The volume of distribution of flumecinol was found to be 41.4 ± 18.4 l/kg. However, the biological half-life of total radioactivity was much longer (35.2 ± 11.9 h) than that of the decrease of unchanged drug. The value of total body clearance (4.1 ± 0.6 l/h) and volume of distribution (3.2 ± 1.6 l/kg) were found to be much lower than that of unchanged flumecinol. Radioactivity excreted with urine was 78.8 ± 5.9% and with faeces 12.0 ± 5.3% during 120 h.

UR - http://www.scopus.com/inward/record.url?scp=0023302852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023302852&partnerID=8YFLogxK

M3 - Article

C2 - 3593454

AN - SCOPUS:0023302852

VL - 37

SP - 368

EP - 371

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 3

ER -